Steris Buys Synergy For $1.9 Billion To Create Sterilization Giant
This article was originally published in The Gray Sheet
The deal for UK-based Synergy follows the trend of U.S. companies moving their headquarters to take advantage of more favorable tax rates, but Steris says the acquisition also makes sense because the companies’ geographies and product ranges are complementary.
You may also be interested in...
The companies plan to contest the Federal Trade Commission's action, although they say they have yet to see FTC's formal complaint. The deal, valued at $1.9 billion, would allow U.S.-based Steris to reduce its corporate tax rate by redomiciling to Synergy's home in the U.K., creating a $2.6 billion entity.
The market for diagnostic and infection control products will see continued growth as hospitals and other providers look to the technology sector to help fight the battle against health care-associated infections and antibiotic-resistant organisms.
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.